In early 2026, the use of genetic testing is becoming standard practice to differentiate between primary, secondary, and genetic forms of focal segmental glomerulosclerosis. These 2026 diagnostic insights allow nephrologists to identify patients with specific mutations who may not respond to traditional immune-modulating drugs, sparing them from unnecessary side effects and directing them...
จองคิวบริการ
NR tours
Youplay
NR shop
NR jobs
facebook th
